专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2013209390A Cycloalkylamine as monoamine reuptake inhibitor 审中-公开
标题翻译：环丙基胺作为单体反应抑制剂
公开(公告)号：JP2013209390A
公开(公告)日：2013-10-10
申请号：JP2013100267
申请日：2013-05-10
申请人： Sunovion Pharmaceuticals Inc , サノビオンファーマシューティカルズインクSunovion Pharmaceuticals Inc.
发明人： SHAO LIMING , WANG FENGJIANG , MALCOLM SCOTT CHRISTOPHER , HEWITT MICHAEL CHARLES , BUSH LARRY R , MA JIANGUO , VARNEY MARK A , CAMPBELL UNA , ENGEL SHARON RAE , HARDY LARRY WENDELL , KOCH PATRICK , CAMPBELL JOHN E
IPC分类号： C07C211/27 , A61K31/135 , A61K31/341 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/40 , A61K31/426 , A61K31/445 , A61K31/4453 , A61K31/495 , A61K31/5375 , A61K31/538 , A61P3/04 , A61P11/16 , A61P13/02 , A61P15/00 , A61P15/02 , A61P25/04 , A61P25/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07C211/29 , C07C211/30 , C07C211/35 , C07C215/00 , C07C215/38 , C07C215/42 , C07C217/52 , C07C217/60 , C07C217/62 , C07C323/32 , C07D207/08 , C07D211/14 , C07D265/14 , C07D277/28 , C07D295/06 , C07D307/52 , C07D317/58 , C07D317/72 , C07D319/06 , C07D333/20
CPC分类号： C07D333/20 , C07C211/17 , C07C211/29 , C07C211/40 , C07C215/42 , C07C215/44 , C07C217/52 , C07C217/74 , C07C323/32 , C07C2601/02 , C07C2601/08 , C07C2601/10 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07D207/06 , C07D207/08 , C07D211/14 , C07D211/16 , C07D265/14 , C07D277/28 , C07D295/06 , C07D307/52 , C07D317/58 , C07D317/72 , C07D319/06 , C07D491/056
摘要： PROBLEM TO BE SOLVED: To provide a cyclohexylamine derivative, to provide a use in treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder, to provide a method for synthesizing the derivative and to provide a pharmaceutical composition containing the derivative.SOLUTION: A compound having a structure represented by a formula (I) is disclosed. In the formula, n is an integer of 0 to 2; s is an integer of 1 to 3; and m is an integer of 0 to 12, wherein, when n is 0, m is 8 or less and, when n is 1, m is 10 or less; Ar is substituted or unsubstituted aryl, etc.; X is H, halogen, etc.; Rand Rare H, halogen, substituted or unsubstituted alkyl, etc.; and Rand Rare H, substituted or unsubstituted alkyl, etc.
摘要翻译：要解决的问题：提供环己胺衍生物，以提供治疗和/或预防中枢神经系统（CNS）障碍如抑郁，焦虑，精神分裂症和睡眠障碍的用途，以提供合成衍生物的方法和提供含有该衍生物的药物组合物。解决方案：公开了具有由式（I）表示的结构的化合物。在该式中，n为0〜2的整数， s为1〜3的整数; m为0〜12的整数，n为0时，m为8以下，n为1时，m为10以下。 Ar是取代或未取代的芳基等; X为H，卤素等; 兰德稀有H，卤素，取代或未取代的烷基等; 和兰德稀土H，取代或未取代的烷基等

2. 发明专利

AU2015202379B2 Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors 未知
公开(公告)号：AU2015202379B2
公开(公告)日：2016-10-13
申请号：AU2015202379
申请日：2015-05-05
申请人： SUNOVION PHARMACEUTICALS INC
发明人： SHAO LIMING , WANG FENGJIANG , MALCOLM SCOTT CHRISTOPHER , HEWITT MICHAEL CHARLES , MA JIANGUO , RIBE SETH , VARNEY MARK A , CAMPBELL UNA , ENGEL SHARON RAE , HARDY LARRY WENDELL , KOCH PATRICK , SCHREIBER RUDY , SPEAR KERRY L
IPC分类号： C07C215/42 , A01N43/00
摘要： PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also disclosed.

3. 发明专利

AU2008259841B2 Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors 未知
公开(公告)号：AU2008259841B2
公开(公告)日：2015-02-05
申请号：AU2008259841
申请日：2008-06-02
申请人： SUNOVION PHARMACEUTICALS INC
发明人： RIBE SETH , MALCOLM SCOTT CHRISTOPHER , SPEAR KERRY L , VARNEY MARK A , SHAO LIMING , WANG FENGJIANG , CAMPBELL UNA , HEWITT MICHAEL CHARLES , SCHREIBER RUDY , MA JIANGUO , HARDY LARRY WENDELL , ENGEL SHARON RAE , KOCH PATRICK
IPC分类号： C07C215/42 , A01N43/00
摘要： Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.

4. 发明专利

AU2015202379A1 Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors 未知
公开(公告)号：AU2015202379A1
公开(公告)日：2015-05-28
申请号：AU2015202379
申请日：2015-05-05
申请人： SUNOVION PHARMACEUTICALS INC
发明人： SHAO LIMING , WANG FENGJIANG , MALCOLM SCOTT CHRISTOPHER , HEWITT MICHAEL CHARLES , MA JIANGUO , RIBE SETH , VARNEY MARK A , CAMPBELL UNA , ENGEL SHARON RAE , HARDY LARRY WENDELL , KOCH PATRICK , SCHREIBER RUDY , SPEAR KERRY L
IPC分类号： C07C215/42 , A01N43/00
摘要： PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also disclosed.

5. 发明专利

ES2594156T3 Cicloalquilaminas como inhibidores de la recaptación de monoaminas 未知
公开(公告)号：ES2594156T3
公开(公告)日：2016-12-16
申请号：ES07716419
申请日：2007-01-05
申请人： SUNOVION PHARMACEUTICALS INC
发明人： SHAO LIMING , WANG FENGJIANG , MALCOLM SCOTT CHRISTOPHER , HEWITT MICHAEL CHARLES , BUSH LARRY R , MA JIANGUO , VARNEY MARK A , CAMPBELL UNA , ENGEL SHARON RAE , HARDY LARRY WENDELL , KOCH PATRICK , CAMPBELL JOHN E
IPC分类号： A61K31/381 , A61K31/335
摘要： Un compuesto que tiene una estructura de acuerdo con la Fórmula (II):**Fórmula** en donde m es un entero de 0 a 12, que no es mayor que 10 Ar es**Fórmula** en donde Y y Z son cada uno independientemente halógeno; o Ar es**Fórmula** en donde Y1, Z1, Y2, Z2 y son miembros seleccionados independientemente del grupo que consiste de: H, halógeno, CN, CF3, OMe, OEt y OCF3; cada X es un miembro seleccionado independientemente del grupo que consiste de H, halógeno, CN, CF3, OR5, SR5, acilo, C(O)OR5, C(O)NR6R7, S(O)2R5, S(O)2NR6R7, NR6R7, NR6S(O)2R5, NR6C(O)R5, alquilo sustituido o no sustituido, heteroalquilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido y heterocicloalquilo sustituido o no sustituido, en donde cada R5, R6 y R7 es un miembro seleccionado independientemente del grupo que consiste de H, acilo, alquilo sustituido o no sustituido, heteroalquilo sustituido o no sustituido, arilo sustituido o no sustituido y heteroarilo sustituido o no sustituido, en donde dos de R5, R6 y R7, junto con los átomos a los que están unidos, se unen opcionalmente para formar un anillo de 3 a 7 miembros; cada R1 y R2 es un miembro seleccionado independientemente del grupo que consiste de H y (C1-C4) alquilo sustituido o no sustituido; R3 y R4 son miembros seleccionados independientemente del grupo que consiste de H, alquilo sustituido o no sustituido y heteroalquilo sustituido o no sustituido; con la condición de que el compuesto no es:**Fórmula** y cualquier sal, enantiómero, diastereómero, mezcla racémica, mezcla enantioméricamente enriquecida, y forma enantioméricamente pura farmacéuticamente aceptable de la misma; en donde los sustituyentes para los radicales alquilo, heteroalquilo y heterocicloalquilo se seleccionan del grupo que consiste de: alquilo no sustituido, heteroalquilo no sustituido, arilo no sustituido, heteroarilo no sustituido, heterocicloalquilo no sustituido-OR', >=O, >=NR' >=N-OR', -NR'R",-SR', -halógeno, -SiR'R"R"', -OC(O)R', -C(O)R', - CO2R', -CONR'R", -OC(O)NR'R",-NR"C(O)R', -NR'-C(O)NR"R"', -NR"C(O)2R', -NR-C(NR'R"R"')>=NR"", - NRC(NR'R")>=NR"', -S(O)R', -S(O)2R', -S(O)2NR'R", -NRSO2R', -CN y -NO2 en un número que varía de cero a (2m'+1), donde m' es el número total de átomos de carbono en tal radical; R', R", R'" y R"" se refieren cada uno independientemente a hidrógeno, heteroalquilo no sustituido, arilo no sustituido, alquilo no sustituido, alcoxi o grupos tioalcoxi, o grupos arilalquilo; y en donde los sustituyentes para los grupos arilo y heteroarilo se seleccionan del grupo que consiste de: alquilo no sustituido, heteroalquilo no sustituido, arilo no sustituido, heteroarilo no sustituido, heterocicloalquilo no sustituido, -- OR', >=O, >=NR' >=N-OR', -NR'R", -SR', -halógeno,-SiR'R"R"', -OC(O)R', -C(O)R', -CO2R', -CONR'R", - OC(O)NR'R", - NR"C(O)R', -NR'-C(O)NR"R"', -NR"C(O)2R', -NR-C(NR'R"R"')>=NR"", -NR-C(NR'R")>=NR"', - S(O)R',-S(O)2R', -S(O)2NR'R", -NRSO2R', -CN, -NO2, -R', -N3, -CH(Ph)2, fluoro(C1-C4)alcoxi, y fluoro(C1- C4)alquilo, en un número que va de cero al número total de valencias abiertas en el sistema de anillo aromático; y donde R', R", R'" y R"" se seleccionan cada uno independientemente de hidrógeno, alquilo no sustituido, heteroalquilo no sustituido, arilo no sustituido y heteroarilo no sustituido.

6. 发明专利

AU2007205114B2 Cycloalkylamines as monoamine reuptake inhibitors 未知
公开(公告)号：AU2007205114B2
公开(公告)日：2012-11-08
申请号：AU2007205114
申请日：2007-01-05
申请人： SUNOVION PHARMACEUTICALS INC
发明人： CAMPBELL UNA , MA JIANGUO , BUSH LARRY R , ENGEL SHARON RAE , HARDY LARRY WENDELL , WANG FENGJIANG , VARNEY MARK A , HEWITT MICHAEL CHARLES , KOCH PATRICK , SHAO LIMING , MALCOLM SCOTT CHRISTOPHER , CAMPBELL JOHN E
IPC分类号： C07C211/03 , A61K31/13 , A61K31/137 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28
摘要： The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式